Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BrainStorm Cell Therapeutics (BCLI), a developer of adult stem cell technologies for neurodegenerative diseases, has signed an agreement with the Mayo Clinic in Rochester, Minnesota to carry out its Phase II clinical trial of NurOwn in amyotrophic lateral sclerosis (ALS), pending FDA approval.
Subscribe to our email newsletter
Additionally, Mayo’s Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants.
The company said that the other two sites scheduled for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.
BrainStorm president Chaim Lebovits said, "We are delighted to be progressing further with our preparations for the trial and honored to be collaborating with Professor Anthony Windebank and the Mayo Clinic."
Mayo Clinic is one of the largest stem cell clinical trial centers across the world, with 27 trials currently in Phase I.
Mayo Clinic professor of Neurology and principal investigator of the study Anthony Windebank said BrainStorm’s mesenchymal stem cell-based approach is very compatible with some of the research conducted in our center.
"This trial is a logical next step in developing novel treatments for ALS which is a terrible disease with no effective treatment for our patients and their families," Windebank added.